PDC*line Pharma Company

PDC*line Pharma develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells.

Headquarters: La Tronche, Rhone-Alpes, France
Investors Number: 10
Last Funding Type: Series B
Funding Status: Early Stage Venture
Employee Number: 1-10
Total Funding: 46226696
Last Funding Date: 2021-12-06
Founded Date: 2014-04-01
Industry: Tumor-Specific Antigens, Whole-Cell Antigens
Estimated Revenue: $1M to $10M